DPM1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P09215(DPM1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The DPM1 antibody is a crucial tool for studying dolichyl-phosphate mannosyltransferase 1 (DPM1), a key enzyme in N-linked glycosylation—a process essential for protein folding, stability, and cellular recognition. DPM1 catalyzes the transfer of mannose from GDP-mannose to dolichyl phosphate, forming dolichyl-phosphate mannose (Dol-P-Man), a lipid-linked sugar donor required for glycosylating proteins in the endoplasmic reticulum (ER). This enzyme is part of a multi-subunit complex, including regulatory subunits DPM2 and DPM3. which stabilize DPM1 and ensure its ER membrane localization.

Mutations in the *DPM1* gene are linked to congenital disorders of glycosylation (CDG), specifically CDG-1e, characterized by developmental delays, seizures, and immune dysfunction. Researchers use DPM1 antibodies to detect protein expression, assess mutations, and study glycosylation defects in clinical or experimental models. Additionally, DPM1 dysregulation has been implicated in cancer progression, as altered glycosylation patterns influence tumor invasiveness and metastasis.

DPM1 antibodies are widely employed in techniques like Western blotting, immunofluorescence, and immunohistochemistry to visualize protein localization, quantify expression levels, and validate disease mechanisms. Their specificity enables insights into ER-associated glycosylation pathways, offering diagnostic and therapeutic potential for glycosylation-related disorders. Overall, DPM1 antibodies serve as vital reagents for unraveling the molecular basis of glycosylation and its implications in human health and disease.